- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Zacks Downgrades DaVita Stock Rating
Analysts lower rating from 'strong-buy' to 'hold' amid mixed analyst views on the dialysis provider's outlook.
Apr. 8, 2026 at 11:34am
Got story updates? Submit your updates here. ›
Analysts at Zacks Research have downgraded their rating on DaVita (NYSE:DVA) stock from 'strong-buy' to 'hold', according to a research note issued to investors on Monday. Several other research firms have also recently weighed in on DaVita, with mixed ratings and price targets.
Why it matters
As one of the leading providers of kidney care services in the U.S., DaVita's stock performance and analyst sentiment can have significant implications for the company's business and the broader dialysis industry. This rating downgrade by a prominent research firm reflects ongoing uncertainty and mixed views about DaVita's future prospects.
The details
In their research note, Zacks analysts cited a number of factors behind the rating downgrade, including recent financial results and the company's future outlook. Other analysts have also issued a range of ratings on DaVita's stock, from 'hold' to 'buy', with varying price targets.
- The Zacks Research rating downgrade was issued on Monday, April 8, 2026.
The players
Zacks Research
A prominent equity research firm that provides investment research and analysis.
DaVita Inc.
A leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers.
What they’re saying
“We have downgraded DaVita's stock rating from 'strong-buy' to 'hold' based on our analysis of the company's recent performance and future outlook.”
— Zacks Research, Equity Research Analysts
The takeaway
This rating downgrade by Zacks Research reflects the ongoing uncertainty and mixed views among analysts about DaVita's future prospects, underscoring the challenges and competitive dynamics facing the dialysis industry. Investors will be closely watching how DaVita responds to this rating change and whether it impacts the company's stock performance going forward.
Denver top stories
Denver events
Apr. 9, 2026
Colorado Avalanche vs. Calgary FlamesApr. 9, 2026
JombrielApr. 9, 2026
Lily Rose - I Know What I Want Tour 2026




